Corresponding Author: Anastasia Khvorova, PhD, RNA Therapeutics Institute, UMass Chan Medical School, 368 Plantation St, Worcester, MA 01605 (anastasia.khvorova@umassmed.edu).
Published Online: June 12, 2023. doi:10.1001/jama.2023.4570
Conflict of Interest Disclosures: Dr Khvorova reports being an unpaid director at large of American Society of Gene & Cell Therapy and scientific council member of the Oligonucleotide Therapeutics Society; founder and scientific adviser of Atalanta Therapeutics, Comanche Biopharma, and Advirna Genomics; reported grants from the National Institutes of Health (Maximizing Investigators’ Research Award) during the conduct of the study; personal fees (scientific advisory board) from Atalanta, Comanche, and Evox outside the submitted work; and more than 30 patents and applications relevant to RNA interference licensed to Atalanta, Comanche, Aldena, and Voyager. All intellectual property is owned and managed by UMass Chan Medical School.